Eli Lilly and Co (LLY)

83.40
NYSE : Health Care
Prev Close 83.40
Day Low/High 0.00 / 0.00
52 Wk Low/High 67.88 / 92.85
Avg Volume 4.21M
Exchange NYSE
Shares Outstanding 1.10B
Market Cap 90.61B
EPS 2.30
P/E Ratio 37.31
Div & Yield 2.04 (2.50%)

Latest News

Eli Lilly (LLY) Announces Resignation of CEO John Lichleiter, CNBC Reports

Eli Lilly (LLY) Announces Resignation of CEO John Lichleiter, CNBC Reports

Eli Lilly (LLY) announced the resignation of CEO John Lichleiter at the end of 2016.

Experimental Tau Protein Drug Tangled Up in Late-Stage Alzheimer's Study Failure

Experimental Tau Protein Drug Tangled Up in Late-Stage Alzheimer's Study Failure

A TauRx Therapeutics drug designed to dissolve tangles of a protein called tau in the brain failed to slow cognitive and functional declines of Alzheimer's patients compared with a control.

Midday Report: New Home Sales Highest Since 2008; U.S. Stocks Mixed

Midday Report: New Home Sales Highest Since 2008; U.S. Stocks Mixed

U.S. stocks retreat into the red as a number of positive and negative earnings reports keep trading choppy.

Dow Slides as McDonald's Disappoints, New Home Sales Climb

Dow Slides as McDonald's Disappoints, New Home Sales Climb

Stocks trade mixed Tuesday as a number of positive and negative earnings report keep traders active.

'Exactly the Trajectory We Want to be On,' Eli Lilly (LLY) CEO Lechleiter Tells CNBC

'Exactly the Trajectory We Want to be On,' Eli Lilly (LLY) CEO Lechleiter Tells CNBC

CEO of the drug manufacturing company Eli Lilly (LLY), John Lechleiter, joined CNBC's "Squawk Box" this morning to discuss the company's second quarter earnings.

Eli Lilly (LLY) Stock Rising After Mixed Q2 Results

Eli Lilly (LLY) Stock Rising After Mixed Q2 Results

Eli Lilly (LLY) stock is increasing in pre-market trading this morning after the pharmaceutical company posted mixed second quarter results before Tuesday's opening bell.

Stock Futures Mixed as Fed Meets, Verizon and McDonald's Tumble

Stock Futures Mixed as Fed Meets, Verizon and McDonald's Tumble

Stock futures are mixed as investors stay on the sidelines ahead of the kickoff to the Federal Reserve's July meeting.

Eli Lilly Has Catalysts Ahead

Eli Lilly Has Catalysts Ahead

Eli Lilly reports earnings on Tuesday. The stock could continue to rise, as the company has several catalysts on the horizon.

Do the Math! Stocks Are Poised for a Fall

Do the Math! Stocks Are Poised for a Fall

Optimism is warranted over the long haul, but investors probably face a short-term headache. Here are the crucial numbers and events to watch in the week ahead.

Week Ahead: Fed's July Meeting Overshadows Another Busy Earnings Week

Week Ahead: Fed's July Meeting Overshadows Another Busy Earnings Week

The Federal Reserve will steal focus from another onslaught of earnings in the coming week as investors remain wary over the central bank's rate-hike timetable.

Analyst: Merck's Fundamentals Don't Warrant Current Valuation

Analyst: Merck's Fundamentals Don't Warrant Current Valuation

BMO Capital Markets downgrades the pharmaceutical giant ahead of Q2 earnings as pricing pressure mounts and other potential headwinds begin to emerge.

Trump VP Pick Mike Pence's Indiana Record Shows Preference for Social Issues Over Business

Trump VP Pick Mike Pence's Indiana Record Shows Preference for Social Issues Over Business

Mike Pence could shore up Donald Trump's support among conservative Christians, but his record on business in Indiana is spotty at best.

3 Stocks Advancing The Health Care Sector

3 Stocks Advancing The Health Care Sector

TheStreet highlights 3 stocks pushing the health care sector higher today.

Lilly And Howard University Partner On Summer Medical Scientific Fellowship

Lilly And Howard University Partner On Summer Medical Scientific Fellowship

Unique program addresses industry's lack of underrepresented minorities

Insider Trading Alert - APOG, LLY And SNCR Traded By Insiders

Insider Trading Alert - APOG, LLY And SNCR Traded By Insiders

Stocks with insider trader activity include APOG, LLY and SNCR

Jim Cramer's 'Mad Money' Recap: What You Can Learn From My Portfolio Mistakes

Jim Cramer's 'Mad Money' Recap: What You Can Learn From My Portfolio Mistakes

Cramer has learned what works and what doesn't at Action Alerts PLUS. Here's how his thinking can help you profit.

6 High-Yield Dividend Stocks With Promising Charts  

6 High-Yield Dividend Stocks With Promising Charts  

The charts look favorable for these six high-yield dividend stocks. The stocks are among Deutsche Bank's list of best long ideas.

Medivation Shares Spike as Company Opens Door to Full-Fledged Auction

Medivation Shares Spike as Company Opens Door to Full-Fledged Auction

The company's shares were up nearly 2% in after hours trading.

Lilly Diabetes Welcomes Acclaimed Singer/Songwriter Crystal Bowersox As Newest Spokesperson

Lilly Diabetes Welcomes Acclaimed Singer/Songwriter Crystal Bowersox As Newest Spokesperson

Singer's moving story aims to help inspire children with type 1 diabetes to pursue their dreams

12 High-Yield Stocks From Deutsche Bank's Best Long Ideas

12 High-Yield Stocks From Deutsche Bank's Best Long Ideas

Following Brexit volatility, Deutsche Bank offered investors 42 best long ideas; here's the 12 stocks from the list with the highest dividend yields.

The Overbought Reading Will Be My Early July Focus

We are into resistance on the major indexes.

Nike Taps Apple CEO Tim Cook for Bigger Role

Nike Taps Apple CEO Tim Cook for Bigger Role

Nike's board of directors features a who's who of Fortune 500 executives.

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Eli Lilly Is on the Verge of a Powerful Breakout

Eli Lilly Is on the Verge of a Powerful Breakout

If Eli Lilly can blow through the $79 area, the stock has plenty of room to run on the upside.

16 Biopharma Companies Besides Medivation That Are Attractive Targets

16 Biopharma Companies Besides Medivation That Are Attractive Targets

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.

FDA Advisory Committee Recommends Approval Of Jardiance® (empagliflozin) For Cardiovascular Indication In 12-11 Vote

FDA Advisory Committee Recommends Approval Of Jardiance® (empagliflozin) For Cardiovascular Indication In 12-11 Vote

Endocrinologic and Metabolic Drugs Advisory Committee votes in favor of CV mortality benefit for JARDIANCE for adults with type 2 diabetes